Rep. Sessions to Newsmax: 'Race Is On' With China in Biotech ...
XBI has “moved higher a record 12 of 13 months,” Mizuho healthcare sector specialist Jared Holz wrote Friday.
The heart-drug developer sent a new signal to biotech investors about what Wall Street is willing to fund in 2026. That is ...
Viking Therapeutics aspires to take market share from both Eli Lilly and Novo Nordisk, and it might succeed.
They have at least one thing in common: An exciting pipeline.
In interviews as well as a panel at BIO’s annual meeting, investors and life sciences bankers predicted an acceleration in ...
Biotechnology is enjoying one of its strongest years in recent times, which is mostly fueled by a rebound in capital markets, ...
As AI transforms biology, longevity startups are attracting investors, advancing toward clinical milestones, and reshaping ...
Inside the social room on the second floor of a building at Lilly Gateway Labs in San Diego, researchers and scientists ...
25d
‘Buying stuff like it’s going out of fashion’: Biotech M&A on track for best year since pre-Covid
Driven by looming patent cliffs, newly buoyant public markets, and Big Pharma's race to beef up their pipelines, dealmaking in 2026 is off to a strong start.
Biotech investors, executives and analysts worry that blanket bans on deals with Chinese companies could curb domestic ...
Patent cliffs are forcing Big Pharma to hunt for revenue-producing biotech assets, and three names keep surfacing in deal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results